ECE2023 Poster Presentations Pituitary and Neuroendocrinology (123 abstracts)
Usefulness of the short version of the acute octreotide test for prediction of first-generation somatostatin receptor ligands response in acromegaly: a validation study with the ACROFAST cohort
Montserrat Marques-Pamies 1 , Joan Gil 2 , Mireia Jorda 3 , Elena Valassi 4 , Betina Biagetti 5 , Marta Hernandez 6,7 , Olga Giménez-Palop 8 , Silvia Martínez 4 , Cristina Carrato 4 , Rocio Villar Taibo 9 , Marta Araujo-Castro 10 , Concepción Blanco 11 , Inmaculada Simón 12 , Andreu Simó-Servat 13 , Gemma Xifra Villarroya 14 , Federico Vazquez San Miguel 4 , Isabel Pavon 15 , Rogelio García Centeno 16 , Roxana Zavala 12 , Felicia Alexandra Hanzu 17 , Mireia Mora 17 , Ana Aulinas Maso 18 , N Vilarrasa 19 , Maria Soledad Librizzi 20 , Maria Paz De Miguel Novoa 21 , Cristina Alvarez-Escola 22 , Antonio Picó-Alfonso 23 , Miguel Antonio Sampedro-Nuñez 24 , Isabel Salinas Vert 4 , Carmen Fajardo-Montañana 25 , Rosa Camara-Gómez 26 , Ignacio Bernabeu 9 , Susan Webb 18 , Monica Marazuela 24 & Manel Puig-Domingo 3,4
1Hospital Municipal Badalona, Endocrinology and Nutrition, Badalona, Spain; 2Germans Trias i Pujol Insitute (IGTP), Endocrine Research Unit, Badalona, Spain; 3IGTP Institut Germans Trias i Pujol, Badalona, Spain; 4Germans Trias i Pujol Hospital, Badalona, Spain; 5Vall d’Hebron, Barcelona, Spain; 6Institut de Recerca Biomèdica de Lleida Fundació Dr. Pifarré, Lleida, Spain; 7Arnau de Vilanova University Hospital, Endocrinology and Nutrition, Lleida, Spain; 8Parc Taulí, Sabadell, Spain; 9Santiago Clinic Hospital CHUS, Santiago de Compostela, Spain; 10Ramón y Cajal, Madrid, Spain; 11Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; 12Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain; 13Hospital Universitari MútuaTerrassa, Terrassa, Spain; 14Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain; 15Getafe University Hospital, Getafe, Spain; 16Gregorio Marañón General University Hospital, Madrid, Spain; 17Hospital Clínic de Barcelona, Barcelona, Spain; 18Hospital de la Santa Creu i Sant Pau, Nou Hospital, Barcelona, Spain; 19Bellvitge University Hospital, L’Hospitalet de Llobregat, Spain; 20University Hospital October 12, Madrid, Spain; 21Hospital Clinico Universitario San Carlos, Madrid, Spain; 22La Paz University Hospital, Madrid, Spain; 23Consortium General University Hospital of Valencia, València, Spain; 24Hospital de La Princesa, Madrid, Spain; 25Hospital Universitari de la Ribera, Alzira, Spain; 26La Fe University and Polytechnic Hospital, València, Spain
We previously described a short version of the acute octreotide test (sAOT) for predicting somatostatin receptor ligands (SRLs) response in patients with acromegaly1. In the present work, we prospectively reassess the sAOT ability to identify SRLs response in patients from the ACROFAST study using the current GH standards and control criteria and we also correlate sAOT values with E-cadherin tumor expression.
Methods: Patients from the ACROFAST study evaluated with the sAOT before receiving any medications and treated with first generation somatostatin analogues. Response to SRLs was evaluated at 6 months of medical treatment in 47 participants: those patients whose IGF1 was <3SDS were considered responders and those with IGF1≥3SDS, non-responders. Additionally, E-cadherin immunohistochemistry expression was investigated in 22/43 patients. The value of GH 2 h after the administration of 100 mg of octreotide subcutaneous (GH2h) was evaluated according to the IGF1 response and to the E-cadherin expression, in order to generate cut-off GH values predicting SRLs response.
Results: 47 patients (30 responders, 17 non-responders) were analyzed. GH2h was higher in non-responder patients (5.04 vs 1.17ng/ml; P<0.01). ROC analysis for predicting non-response with GH2h cut-off showed an Area Under Curve of 0.832. A GH2h value of 4.3ng/ml was the best cut-off for non-response prediction, with a Positive Predictive Value of 92% (Sensitivity 35%; Specificity 97%). The cut-off for GH2h of 1.4ng/ml showed the highest ability to identify responders with a Negative Predictive Value for non-response of 92% (Sensitivity 94%, Specificity 73%). Patients with E-cadherin expression tumors presented a lower GH2h compared with tumors with low or no E-cadherin expression (1.29 vs 5.69ng/ml; P<0.01).
Conclusions: The sAOT is a good predictor tool for assessing SRLs treatment response and correlates with E-cadherin tumor expression, thus being useful in clinical practice in patients with acromegaly for the medical therapeutic decision-process.
Reference: 1. Halperin I, Nicolau J, Casamitjana R, Sesmilo G, Serra-Prat M, Palomera E, Puig-Domingo M. A Short Acute Octreotide Test for Response Prediction of Long-term Treatment with Somatostatin Analogues in Acromegalic Patients. Hormone and Metabolic Research 2008 40 422-426. (https://doi.org/10.1055/s-2008-1065339)
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more